Effects of atorvastatin on apelin, visfatin (nampt), ghrelin and early carotid atherosclerosis in patients with type 2 diabetes

Acta Diabetologica

Volumn 49, Issue 4, 2012, Pages 269-276

  Kadoglou, Nikolaos P E ^a   Sailer, Nikolaos ^a   Kapelouzou, Alkistis ^b   Lampropoulos, Stylianos ^c   Vitta, Ioulia ^a   Kostakis, Alkiviadis ^b   Liapis, Christos D ^d  

^a Aristotle University and Hippokration General Hospital   (Greece)

^b BIOMEDICAL RESEARCH FOUNDATION   (Greece)

^c Mpodosakio General Hospital of Ptolemaida   (Greece)

^d UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Apelin; Carotid intima media thickness; Ghrelin; Statins; Type 2 diabetes; Visfatin (nampt)

Indexed keywords

ADIPOCYTOKINE; APELIN; ATORVASTATIN; C REACTIVE PROTEIN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GHRELIN; INSULIN; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; SULFONYLUREA;

ADULT; AGE; AGED; ARTERIAL WALL THICKNESS; ARTICLE; ATHEROSCLEROSIS; BLOOD PRESSURE MONITORING; BODY MASS; CAROTID ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; DRUG ACTIVITY; DRUG DOSE COMPARISON; DRUG DOSE TITRATION; DRUG MEGADOSE; FEMALE; GLYCEMIC INDEX; HUMAN; INSULIN RESISTANCE; LIPID ANALYSIS; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; SEX DIFFERENCE;

AGED; CAROTID ARTERY DISEASES; CAROTID INTIMA-MEDIA THICKNESS; CYTOKINES; DIABETES MELLITUS, TYPE 2; FEMALE; GHRELIN; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MIDDLE AGED; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; PYRROLES;

EID: 84864959779     PISSN: 09405429     EISSN: 14325233     Source Type: Journal    
DOI: 10.1007/s00592-011-0310-0     Document Type: Article

References (40)

1. Riccioni G, Vitulano N, Mancini B, Zanasi A, D'Orazio N (2010) One-year treatment with rosuvastatin reduces intima-media thickness in 45 hypercholesterolemic subjects with asymptomatic carotid artery disease. Pharmacology 85:63-67
2. Zoungas S, Patel A (2010) Cardiovascular outcomes in type 2 diabetes: the impact of preventative therapies. Ann N Y Acad Sci 1212:29-40
3. Lardizabal JA, Deedwania PC (2010) Benefits of statin therapy and compliance in high risk cardiovascular patients. Vasc Health Risk Manag 6:843-853
4. Khan T, Hamilton MP, Mundy DI, Chua SC, Scherer PE (2009) Impact of simvastatin on adipose tissue: pleiotropic effects in vivo. Endocrinology 150:5262-5272
5. Schaefer C, Biermann T, Schroeder M et al (2010) Early microvascular complications of prediabetes in mice with impaired glucose tolerance and dyslipidemia. Acta Diabetol 47(Suppl 1):19-27
6. King GA, Deemer SE, Thompson DL (2010) Adiponectin is associated with risk of the metabolic syndrome and insulin resistance in women. Acta Diabetol Epub ahead of print
7. Dray C, Debard C, Jager J et al (2010) Apelin and APJ regulation in adipose tissue and skeletal muscle of type 2 diabetic mice and humans. Am J Physiol Endocrinol Metab 298:E1161-E1169
8. Kadoglou NP, Lampropoulos S, Kapelouzou A, Gkontopoulos A, Theofilogiannakos EK, Fotiadis G, Kottas G (2010) Serum levels of apelin and ghrelin in patients with acute coronary syndromes and established coronary artery disease-KOZANI STUDY. Transl Res 155:238-246
9. Wang Z, Nakayama T (2010) Inflammation, a link between obesity and cardiovascular disease. Mediators Inflamm 2010 535918
10. Tasci I, Erdem G, Ozgur G, Tapan S, Dogru T, Genc H, Acikel C, Ozgurtas T, Sonmez A (2009) LDL-cholesterol lowering increases plasma apelin in isolated hypercholesterolemia. Atherosclerosis 204:222-228
11. Moschen AR, Gerner RR, Tilg H (2010) Pre-B cell colony enhancing factor/NAMPT/visfatin in inflammation and obesityrelated disorders. Curr Pharm Des 16:1913-1920
12. Kadoglou NP, Sailer N, Moumtzouoglou A et al (2010) Visfatin (nampt) and ghrelin as novel markers of carotid atherosclerosis in patients with type 2 diabetes. Exp Clin Endocrinol Diabetes 118:75-80
13. Ozgen M, Koca SS, Aksoy K, Dagli N, Ustundag B, Isik A. (2010) Visfatin levels and intima-media thicknesses in rheumatic diseases. Clin Rheumatol [Epub ahead of print]
14. Kostapanos MS, Derdemezis CS, Filippatos TD, Milionis HJ, Kiortsis DN, Tselepis AD, Elisaf MS (2008) Effect of rosuvastatin treatment on plasma visfatin levels in patients with primary hyperlipidemia. Eur J Pharmacol 578:249-252
15. Derdemezis C, Filippatos T, Tselepis A, Mikhailidis D, Elisaf M (2008) Effects of ezetimibe, either alone or in combination with atorvastatin, on serum visfatin levels: a pilot study. Expert Opin Pharmacother 9:1829-1837
16. Suzuki K, Simpson KA, Minnion JS, Shillito JC, Bloom SR (2010) The role of gut hormones and the hypothalamus in appetite regulation. Endocr J 57:359-372
17. Otto C, Otto B, Frost RJ, Vogeser M, Pfeiffer AF, Spranger J, Parhofer KG (2007) Short-term therapy with atorvastatin or fenofibrate does not affect plasma ghrelin, resistin or adiponectin levels in type 2 diabetic patients with mixed hyperlipoproteinaemia. Acta Diabetol 44:65-68
18. National cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) (2002) Third report of the national cholesterol education program (NCEP); expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation 106:3143-21
19. Roman MJ, Naqvi TZ, Gardin JM, Gerhard-Herman M, Jaff M, Mohler E (2006) American society of echocardiography; society for vascular medicine and biology. American society of echocardiography report clinical application of non-invasive vascular ultrasound in cardiovascular risk stratification: a report from the American society of echocardiography and the society for vascular medicine and biology. Vasc Med 11:201-1121
20. Salonen R, Seppänen K, Rauramaa R, Salonen JT (1988) Prevalence of carotid atherosclerosis and serum cholesterol levels in eastern Finland. Arteriosclerosis 8:788-792
21. Yue P, Jin H, Aillaud M et al (2010) Apelin is necessary for the maintenance of insulin sensitivity. Am J Physiol Endocrinol Metab 298:E59-E67
22. Pitkin SL, Maguire JJ, Kuc RE, Davenport AP (2010) Modulation of the apelin/APJ system in heart failure and atherosclerosis in man. Br J Pharmacol 160:1785-1795
23. Krysiak R, Gdula-Dymek A, Bachowski R, Okopien B (2010) Pleiotropic effects of atorvastatin and fenofibrate in metabolic syndrome and different types of pre-diabetes. Diabetes Care 33:2266-2270
24. Erdem G, Dogru T, Tasci I, Sonmez A, Tapan S (2008) Low plasma apelin levels in newly diagnosed type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes 116:289-292
25. Kuklinska AM, Sobkowicz B, Sawicki R, Musial WJ, Waszkiewicz E, Bolinska S, Ma?yszko J (2010) Apelin: a novel marker for the patients with first ST-elevation myocardial infarction. Heart Vessels 25:363-367
26. Wang P, Vanhoutte PM, Miao CY (2011) Visfatin and cardiocerebro-vascular disease. J Cardiovasc Pharmacol [Epub ahead of print]
27. Kadoglou NP, Gkontopoulos A, Kapelouzou A, Fotiadis G, Theofilogiannakos EK, Kottas G, Lampropoulos S (2011) Serum levels of vaspin and visfatin in patients with coronary artery disease-Kozani study. Clin Chim Acta 412:48-52
28. Liu SW, Qiao SB, Yuan JS, Liu DQ (2009) Association of plasma visfatin levels with inflammation, atherosclerosis and acute coronary syndromes (ACS) in humans. Clin Endocrinol (Oxf) 71:202-207
29. Pfützner A, Hanefeld M, Lübben G, Weber MM, Karagiannis E, Köhler C, Hohberg C, Forst T (2007) Visfatin: a putative biomarker for metabolic syndrome is not influenced by pioglitazone or simvastatin treatment in nondiabetic patients at cardiovascular risk-results from the PIOSTAT study. Horm Metab Res 39:764-768
30. Dogru T, Sonmez A, Tasci I et al (2007) Plasma visfatin levels in patients with newly diagnosed and untreated type 2 diabetes mellitus and impaired glucose tolerance. Diabetes Res Clin Pract 76:24-29
31. Fan Y, Meng S, Wang Y, Cao J, Wang C (2011) Visfatin/PBEF/Nampt induces EMMPRIN and MMP-9 production in macrophages via the NAMPT-MAPK (p 38, ERK1/2)-NF-jB signaling pathway. Int J Mol Med 27:607-615
32. Dahl TB, Yndestad A, Skjelland M et al (2007) Increased expression of visfatin in macrophages of human unstable carotid and coronary atherosclerosis: possible role in inflammation and plaque destabilization. Circulation 115:972-980
33. Kellokoski E, Kummu O, Serpi R, Lehenkari P, Ukkola O, Kesäniemi YA, Hörkkö S (2009) Ghrelin vaccination decreases plasma MCP-1 level in LDLR(-/-)-mice. Peptides 30:2292-2300
34. Berthold HK, Giannakidou E, Krone W, Trégouët DA, Gouni-Berthold I (2010) Influence of ghrelin gene polymorphisms on hypertension and atherosclerotic disease. Hypertens Res 33:155-160
35. Tesauro M, Schinzari F, Iantorno M, Rizza S, Melina D, Lauro D, Cardillo C (2005) Ghrelin improves endothelial function in patients with metabolic syndrome. Circulation 112:2986-2992
36. Ukkola O (2009) Ghrelin and metabolic disorders. Curr Protein Pept Sci 10:2-7
37. Zhao H, Liu G, Wang Q, Ding L, Cai H, Jiang H, Xin Z (2007) Effect of ghrelin on human endothelial cells apoptosis induced by high glucose. Biochem Biophys Res Commun 362:677-681
38. Li WG, Gavrila D, Liu X et al (2004) Ghrelin inhibits proinflammatory responses and nuclear factor-kappaB activation in human endothelial cells. Circulation 109:2221-2226
39. Mafra D, Farage NE,Lobo JC, Stockler-PintoMB,Leal VO,Carvalho DP, Leite M Jr et al (2011) Relationship between total ghrelin and inflammation in hemodialysis patients. Peptides 32:358-361
40. Kadoglou NP, Tsanikidis H, Kapelouzou A, Vrabas I, Vitta I, Karayannacos PE, Liapis CD, Sailer N (2010) Effects of rosiglitazone and metformin treatment on apelin, visfatin, and ghrelin levels in patients with type 2 diabetes mellitus. Metabolism 59:373-379